Takeda Pharmaceutical Co. Ltd. and Affymax, Inc. Announce Supply Agreement for OMONTYS® (peginesatide) Injection With Fresenius Medical Care North America
Published: Jul 12, 2012
DEERFIELD, Ill. & PALO ALTO, Calif.--(BUSINESS WIRE)--Takeda Pharmaceuticals U.S.A. (TPUSA) and Affymax, Inc. (Nasdaq:AFFY) today announced that Takeda Pharmaceuticals America, Inc. (TPA) has entered into a supply agreement for sourcing and supply of OMONTYS® (peginesatide) Injection to Fresenius Medical Care North America and certain of its affiliates. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population with chronic kidney disease (CKD) in the United States.